Abstract: Psoriasis is a chronic inflammatory disease that affects 1.3% of the Brazilian population. The most common clinical manifestations are erythematous, scaling lesions that affect both genders and can occur on any anatomical site, preferentially involving the knees, elbows, scalp and genitals. Besides the impact on the quality of life, the systemic nature of the disease makes psoriasis an independent risk factor for cardiovascular disease, especially in young patients with severe disease. By an initiative of the Brazilian Society of Dermatology, dermatologists with renowned clinical experience in the management of psoriasis were invited to form a work group that, in a partnership with the Brazilian Medical Association, dedicated themselves to create the Plaque Psoriasis Diagnostic and Treatment Guidelines. The relevant issues for the diagnosis (evaluation of severity and comorbidities) and treatment of plaque psoriasis were defined. The issues generated a search strategy in the Medline-PubMed database up to July 2018. Subsequently, the answers to the questions of the recommendations were devised, and each reference selected presented the respective level of recommendation and strength of scientific evidence. The final recommendations for making up the final text were worded by the coordinators.
INTRODUCTION
In 
OBJECTIVE
To establish the recommendations for the diagnosis (assessment of severity and comorbidities) and the treatment of plaque psoriasis.
TOOLS OF SEVERITY ASSESSMENT
With the aim of evaluating the role of the assessment tools applied to psoriasis patients, a Medline-PubMed database search was conducted, resulting in 984 studies, of which 14 were selected to answer to the clinical question. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] What is the role of the assessment tools PASI, BSA, DLQI and PGA for the assessment of severity and therapeutic response of plaque psoriasis?
PASI
In the PASI (Psoriasis Area Severity Index) score, the evaluator should observe the erythema, thickness, scaling, and the percentage of the area affected of four regions (head/neck, trunk, lower and upper limbs) and calculate the score, which varies from 0 to 72 (B). 15 In the evaluation of severity in plaque psoriasis patients, the PASI tool demonstrated adequate content validity and internal consistency and moderate intraobserver variation. Despite some limitations, PASI can be recommended for the scientific evaluation of the severity of plaque psoriasis (B). 16 
. 2 P G A This tool [Physician´s Global Assesment (PGA)] only
evaluates the features of the lesion, measuring the degree of erythema, scaling and thickness of psoriasis lesions of the whole body, grading in a six-point scale, ranging from 0 (no lesion) to 6 (severe);
however, it does not provide information on the extension of the disease (B). 15 It demonstrated adequate content validity, moderate interobserver variation and low intraobserver variation (B). . 15 It demonstrated little intraobserver variation, however, an unacceptable interobserver variation for the evaluation of the severity of disease. It is not adequate to define psoriasis severity because it does not assess the intensity of the lesion (B). 16 
DLQI
The Dermatology Life Quality Index (DLQI) measures the impact of the skin disease in the quality of life of the patient in the last seven days. It consists of 10 items, six dimensions and one overall summary score. Each question has four alternative answers: "not at all", "a little", "a lot" or "very much", with scores of 0, 1, 2 and 3, respectively. The overall summary score aggregates the score of each item and ranges between 0 (the best score) and 30
(the worst score). (B). 10 In plaque psoriasis patients, the DLQI tool demonstrated adequate content validity, construct validity, internal consistency, replicability, acceptability and sensitivity in appropriately detecting changes in the disease (B). 4 Due to its briefness and simplicity, it is useful for the clinical practice (B). 1.5 NAPSI NAPSI (Nail Psoriasis Severity Index) is used to evaluate the severity of psoriasis in the nail bed and nail matrix. The nail plate is divided into quadrants using an imaginary longitudinal and horizontal lines. The involvement of the nail matrix and nail bed is assessed, and the score ranges from 0 to 8 per nail. The tool is replicable and the analysis is simplified (B). 13 Although it has a few limitations (B), the scoring agreement among observers was considered between good to moderate with NAPSI (B).
2,9
FIgure 4: Prevalence of Asthma/COPD in moderate to severe plaque psoriasis patients
FIgure 5: Prevalence of chronic liver disease in moderate to severe plaque psoriasis patients
Systemic hypertension
The prevalence of systemic hypertension (SHT) in psoriasis patients in the random effects model is of 26.9% (CI 95%: 21.5-33; Figure 9 ).
Diabetes mellitus
The prevalence of diabetes mellitus (DM) in psoriasis patients in the random effects model is of 11.7% (CI 95%: 8.9-15.2; Figure 10 ).
Coronary insufficiency
The prevalence of ischemic cardiomyopathy or coronary insufficiency in psoriasis patients in the random effects model is of 3.4% (CI 95%: 2.3-5%; Figure 11 ).
Inflammatory bowel disease
The prevalence of inflammatory bowel disease in psoriasis patients in the random effects model is of 0.9% (CI 95%: 0.6-1.3; Figure 12 ).
Migraine
The prevalence of migraine in psoriasis patients in the random effects model is of 15.5% (CI 95%: 0.3-84.8; Figure 13 ).
Other comorbidities
Other prevalent comorbidities in psoriasis patients were alexithymia; other dermatological conditions such as seborrheic dermatitis, acne, rosacea; pulmonary hypertension; and celiac disease (Table 1) In a study that evaluated clobetasol propionate lotion, cream or its vehicle, the use of lotion and cream showed significant and similar improvement (p<0.001). There was a reduction of lesions in 55% of patients using clobetasol propionate in both groups of active treatment (NNT=2) on the fourth week. Three patients of each treatment group with the active ingredient reported telangiectases, and four patients in the group using clobetasol cream reported mild to moderate skin atrophy (A). 92 The use of 0.05% clobetasol propionate foam for two weeks was more effective than placebo (vehicle with no active ingredient), with improvement ranging from 47% to 22% (placebo) of patients reaching PGA score 0 or 1 (p<0.0001, NNT=3). The most common adverse event was burning sensation on the area of application (5% of the patients in the intervention group and 7% of the comparison group). There were no severe side effects, (A). 97, 108 The use of betamethasone valerate (BMV) on one side of the body and placebo on the other side, twice daily for 12 weeks lead to at least 50% improvement against 24% in the placebo group (NNT= 4). Adverse events were limited, being burning sensation and pruritus the most common (A). 114 
96
The safety and efficacy of 0.005% fluticasone propionate ointment for four weeks was evaluated, in comparison with its vehicle. There was significantly more improvement in the intervention group (p<0.0001) measured by PGA 0/1 between 29.4% (NNT=4) and 36% (NNT=3). The adverse events were mild to moderate, the most common being burning sensation and pruritus on the area of application, which occurred in 6% of patients, both in the intervention and the comparison group (A). 109 
Dyslipidemia Prevalence
FIgure 9: Prevalence of systemic hypertension in moderate to severe plaque psoriasis patients In the comparison between 0.05% betamethasone propionate ointment, its ointment vehicle and 0.05% diflorasone diacetate ointment, the group using betamethasone showed a faster improvement, seen already on the first week of treatment, with significant difference in relation to the group using diflorasone or to the control group (p=0.01). The improvement seen was maintained on the third week. The adverse events were minimal (A).
105

Recommendations:
In plaque psoriasis, the use of the topical corticosteroids clobetasol propionate, betamethasone valerate and fluticasone propionate, proved to be significantly effective in improving signs and symptoms of erythema, scaling, thickness of the plaque and pruritus, besides the significant improvement in the evaluation of the physician or the patient regarding clearance of the lesions. The most frequent adverse events were burning sensation and stinging on the area of application, both with the active ingredient and the placebo, with no significant difference among the comparison groups.
What is the efficacy and risk of tar derivatives (coal tar and liquor carbonis detergens -LCD) for the treatment of psoriasis?
The use of 2% dithranol ointment, for one minute, once daily, associated to UVB phototherapy, resulted in significant clearance measured by the physician and the patient after eight weeks, except for pruritus (p=0.004). The adverse event reported during the study was skin irritation on the area of application (A).
42
Recommendations:
Of the tar derivatives, only dithranol (associated to phototherapy) showed significant efficacy in the improvement of erythema, scaling and thickness of psoriasis plaques, not being effective for the improvement of pruritus. The adverse event observed with dithranol was local skin irritation.
There are no evidences that allow for the recommendation of coal tar and Liquor Carbonis Detergens for the treatment of Plaque Psoriasis.
Prevalence Systemic hypertension
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FIgure 10: Prevalence of diabetes mellitus in moderate to severe plaque psoriasis patients
What is the efficacy and risk of topical calcineurin inhibitors for the treatment of psoriasis?
The use of 6% salicylic acid gel associated to 0.1% tacrolimus ointment twice daily, on one side of the body, compared to 6% salicylic acid gel associated to placebo on the other side, lead to an improvement in the pruritus, erythema and scaling on weeks 1, 2 and 8 (p<0.05), as well as a significant improvement in the global assessment of the disease in week 8, except for the evaluation of erythema (A). 90, 90 In a study that evaluated twice-daily 0.005% calcipotriol ointment or once-daily 0.3% tacrolimus ointment or placebo, there was no significant reduction in PASI with the use of topical tacrolimus in relation to placebo (p=0.77) (A).
116
Recommendations:
Regarding the topical use of calcineurin inhibitors, tacrolimus does not show significant improvement in PASI reduction. However, in an evaluation eight weeks after starting the application, it proved to be effective for the improvement of pruritus, erythema and scaling of psoriatic plaques. When using the global assessment index from 0 to 5 points, there is no significant improvement in the erythema with the use of tacrolimus. There is no response evaluation after eight weeks of follow-up.
What is the efficacy and the risk of vitamin D analogues for the treatment of psoriasis?
Calcipotriol ointment at 0.05% significantly improved lesions compared to the control group (p<0.001) (A), however, the active ingredient in a cream, in the same concentration did not show improvement when compared to placebo (p=0.12).
112
In the physician's global assessment there is also a statistically significant difference between treatments, favoring twice-daily 0.005% calcipotriol, since the first week (p<0.001), which was maintained after the eighth week of treatment (A). 
94
In the investigator's global assessment, 56%, 22% and 22%
of patients using twice-daily 50µg/mg calcipotriol ointment for eight weeks showed moderate or marked improvement or clearance, respectively (p<0.004) (A). 104 When evaluating the use of 0.005% calcipotriol foam according to the PGA, between 7% (p=0.058, NNT=15) and 11% (p=0.016, NNT=9) of patients achieved PGA 0/1 for the intervention group in the study. The adverse events were reported in 1 to 2 % of patients
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FIgure 13: Prevalence of migraine in moderate to severe plaque psoriasis patients (irritation, erythema, or pruritus on the area of application) (A).
95
When compared to placebo, the use of 3 µg/g calcitriol showed difference between 11.9% (p=0.05, NNT=9) and 21% (p<0.01, NNT=5) in the physician's global assessment. The adverse events reported were mild, and included discomfort, pruritus or erythema (A).
107
The efficacy evaluation of 15 µg/g calcitriol according to the PASI score, showed there was a significant difference of response of 81% favoring topical treatment with calcitriol after two months of follow-up (NNT=2). Nonetheless, in the control group, 83.3% did not show any changes in the lesions and 1.2% had worsening (A). 111 Regarding PGA, when 15µg/g calcitriol was evaluated on one side of the body and its vehicle on the other side, there was a significant difference between the treatments on both sides of the body from the first week (p=0.0004), which was maintained after the sixth week (p=0.002), favoring calcitriol use (NNT=3) (A).
106
Recommendations:
Vitamin D analogues, 50 µg/g calcipotriol ointment, 0.005% calcipotriol foam and 6µg/g calcitriol, were shown to be effective for the topical treatment of plaque psoriasis in a period of 4 to 16 weeks for the analysis of clinical features like erythema, scaling and plaque thickness, and for PASI and the investigator's or patient's global assessment. This class of drugs proved to be safe, since most side effects are mild and related to reactions on the areas of application such as erythema, pruritus and burning sensation. The comparison between 50µg/g calcipotriol associated to 0.5mg/g betamethasone, or 50µg/g calcipotriol alone, or 0.5mg/g betamethasone alone, when the SUM score is used (it evaluates erythema, thickness and scaling in the lesion), demonstrates that the mean percentage of score reduction in four weeks is of 61% for the combination of drugs, 32% for calcipotriol alone and 41% for betamethasone alone; on the sixth week, this reduction was of 58%, 45%
and 56%, respectively (A).
115
When the difference in PASI change (in percentage) between the combination of drugs compared to betamethasone alone was evaluated, the result was 10.3% (CI95% 5.8% to 14.7%, p<0.001, NNT=10). (A). 110 If the mean PASI difference is evaluated in points during the treatment, the result was -13.1 for the intervention group (CI95% -16.9 to -9.3, p<0.001) in one study (A) and -14.2 for the intervention group (CI95% -17.6 to -10.8, p<0.001) in another (A) in up to eight weeks. 93, 102 Side effects were mild and comparable between the groups analyzed (A).
93,102
Recommendations:
In plaque psoriasis lesions, the use of calcipotriol associated to topical betamethasone shows statistically significant improvement in comparison to the use of the topical corticosteroid alone, in a period of assessment of 4 to 8 weeks, regarding the evaluation with the PASI score. 93 In regards to the number of daily applications, there was no difference between once-or twice-daily application in efficacy measurements, being the combination calcipotriol/betamethasone always superior in comparison to calcipotriol alone. The most common adverse events were local and mild, with pruritus being the most frequent (A).
98
Recommendations:
The use of calcipotriol associated to topical betamethasone demonstrates a statistically significant improvement in relation to the use of topical calcipotriol alone for plaque psoriasis lesions in the period of 2 to 8 weeks of evaluation.
PHOTOTHERAPY
With the aim of establishing the recommendations on the efficacy and safety of phototherapy for plaque psoriasis, a search was carried out in the Medline-PubMed database, resulting in 436 studies, with 09 selected to answer the clinical questions.
What is the efficacy and risk of phototherapy for the treatment of psoriasis?
In the evaluation of the treatment of plaque psoriasis with the concurrent use of narrowband ultraviolet B (NB-UVB) phototherapy and fumaric acid esters and the use of fumaric acid esters alone, it was observed that the NB-UVB combined treatment led to a higher median reduction in the PASI score in six weeks of treatment, when compared to the use of fumaric acid alone (p=0.016), therefore, with a higher positive impact in the quality of life (p=0.031) and less side effects (A). 117 In a study that compared NB-UVB phototherapy, the association of NB-UVB with methotrexate and methotrexate alone, there was no difference in the concurrent use of methotrexate (MTX) 
What are the advantages and disadvantages of NB-U-
VB in relation to PUVA?
A study proved NB-UVB to be superior to PUVA for plaque psoriasis, with 75% of achieving complete resolution in the NB-UVB versus 54% in the PUVA group. There was no significant difference between the groups regarding time for remission, neither in the number of adverse events (A). 125 When comparing NB-UVB with the use of UVA associated to trisoralen, there was a median PASI reduction in 32% favoring UVB phototherapy (p<0.001, NNT=3) (A).
126
A study showed that, in patients with skin phototype I to IV, PUVA was significantly more effective than NB-UVB regarding response to resolution (84% vs. 65%, p=0.02, NNT=6), but with more side effects and longer treatment time for clearance of lesions (A).
127
Another similar study showed that clearance of psoriasis lesions was achieved in a significantly higher proportion of patients treated with PUVA (84%) compared to those treated with NB-UVB (63%) (CI95%, 1.18 to 7.84, p=0.018, NNT=5), but at the expense of more side effects (A). 128 When PASI median was evaluated, treatment with PUVA showed a significantly higher reduction in PASI median than in the NB-UVB group (26.72%, CI 95%, p=0.005, NNT=4) (A).
129
The index of resolution with NB-UVB was of 80% in patients pre--treated with topical retinoids, compared to a 90% index in patients pre-treated with topical retinoids that were submitted to NB-UVB, and an index of 100% in patients using PUVA ant topical retinoids
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concomitantly (A). 129 The association of etretinate and PUVA lead to 100% of complete improvement in a study, while the association of the medication with NB-UVB improved 80% of patients. 130 When the combined treatment of phototherapy and acitretin was analyzed, psoriasis clearance was seen in 56.6% of patients treated with NB-UVB and in 63.3% of patients treated with PUVA (A).
131
In other studies, no difference in improvement as measured by PASI was observed between the use of NB-UVB and PUVA in the treatment of plaque psoriasis, (A), but there seems to be a higher frequency of side effects in patients using PUVA (A).
132,133
Evaluating a 0 to 4 index similar to PGA for the treatment of palmoplantar psoriasis, a higher percentage in the reduction of the index with PUVA (85.45%) was observed, rather than with NB-UVB (61.08%-p=0.0001) (A).
134
Recommendations:
In the efficacy comparison between NB-UVB and PUVA, most studies demonstrate a higher efficacy of PUVA in relation to NB-UVB in the evaluation of up to 3 months of treatment, although there is evidence that NB-UVB can occasionally be superior. The mean number of necessary treatments for clearance of the lesions was also significantly lower in patients undergoing PUVA, compared to patients undergoing UVB. The most frequent adverse events in all treatments were mucocutaneous xerosis, erythema, pruritus and nausea, most of the times mild, not interfering with the treatments.
CLASSIC SYSTEMIC TREATMENT
With the aim of establishing recommendations on the classic treatment for plaque psoriasis (acitretin, methotrexate and cyclosporine), a search was carried out using the Medline-PubMed database and the best scientific evidences were selected to answer the clinical questions.
What is the efficacy and risk of methotrexate in the systemic treatment of psoriasis?
Patients diagnosed with plaque psoriasis (n=120) were treated with methotrexate 17.5mg SC once weekly or placebo injections in the first 16 weeks of the study (phase 1). In the second phase of the study (weeks 16 to 52), all patients were treated with metho- There was a statistically significant improvement in the complete resolution of lesions (PASI 100) in the patients treated with adalimumab (16.7%) in relation to patients treated with methotrexate (7.3%) or in patients treated with placebo (1.9%). Regarding adverse events, there was no statistically significant difference between the groups for infections, moderate to severe adverse events and adverse events related to the drugs. More adverse events lead to discontinuation of the study in the methotrexate group, mainly due to the events related to liver dysfunction. (A). 136, 137 Recommendations:
In the treatment of moderate to severe psoriasis with methotrexate, there is significant PASI reduction in relation to baseline at 2, 4 and 6 months of evaluation when compared to placebo, with a number necessary to treat varying from 3 to 6 patients. The most frequent adverse events are nausea, vomiting and abnormalities in transaminases.
What is the efficacy and risk of acitretin in the systemic treatment of psoriasis?
A randomized, double-blind study evaluated the efficacy and safety of oral acitretin in the treatment of moderate to severe plaque psoriasis, in three treatment groups with different doses:
25mg, 35mg or 50mg/day. Clinical improvement was observed in all groups with PASI 75 response at week 12. The mean PASI dropped 76% in the 35mg group after 12 weeks of treatment, this difference was statistically significant compared to the 25mg and 50mg groups (p<0.05). In the evaluation at 12 weeks of treatment, PASI 75 response was achieved in 47%, 69% and 53% patients in the 25, 35 and 50mg/day acitretin groups, respectively. Most adverse events were mucocutaneous, mild to moderate and dose-dependent (A).
138
In another study, patients with moderate to severe plaque psoriasis were randomized to the following doses of acitretin: eight patients using 10mg to 25mg per day, or 16 patients using 50mg to 75mg per day. Patients treated with acitretin doses of 50 to 75mg
per day showed a significant therapeutical response (p<0.05) in the evaluation at eight weeks. More adverse events occurred in patients receiving the dose of 25mg per day or more of acitretin, but usually mild and with no need to discontinue the treatment(A).
139
Recommendations:
In patients with moderate to severe plaque psoriasis, the use of doses of acitretin of 35 to 75mg per day showed significant improvement, evaluated by the PASI response. The most frequently observed adverse events are cheilitis, scaling of palmoplantar regions and alopecia, however, the need to discontinue the treatment was rare. 
What is the efficacy and risk of cyclosporine in the sys
140
A study evaluated the efficacy and safety of cyclosporine for the treatment of severe psoriasis (PASI ≥ 18), in two different dosing regimens: 2.5mg/kg/day and 5mg/kg/day. The mean PASI score reduction at the end of the induction phase was 69% in the 2.5mg/kg/ day group and 89% in the 5mg/kg/day group (p=0.0001, NNT=5).
Eighty-six percent of patients described some adverse event during the treatment period (for up to 21 months), most of them mild to moderate. The most frequent events were systemic hypertension, hirsutism/hypertrichosis, headache, paresthesia, nausea, abdominal discomfort, flu-like symptoms, fatigue, tremor, edema and renal abnormalities. The severe adverse events reported were the development of malignancies in eight patients (of those, four were skin cancers) and two patients had myocardial infarction (A).
141
In another study, the efficacy and safety of cyclosporine for the treatment of moderate to severe plaque psoriasis was evaluated in two different dosing regimens. One of the groups initially received cyclosporine 1.25mg/kg/day, increasing to 2.5mg/kg/day or 5mg/kg/day in cases where there was no PASI reduction of 10% in two weeks or 30% in six weeks. Another group for comparison received cyclosporine 2.5mg/kg/day, increasing to 5mg/kg/day in the cases where there was no PASI reduction of 10% in two weeks or 30% in six weeks. After 12 weeks of treatment, 18% of patients with the initial dose of 1.25mg/kg/day and 56% of patients with the initial dose of 2.5mg/kg/day showed a PASI 75 response. The most frequent adverse events were gastrointestinal abnormalities and viral infections (B).
142
Recommendations:
The use of cyclosporine in moderate to severe plaque psoriasis demonstrates significant improvement evaluated by the PASI response, with the best responses obtained with the dose of 5mg/ kg/day. The most important severe adverse events were reported in long treatments (21 months), encompassing malignancies and systemic hypertension. For those patients who showed an adequate therapeutic response in up to 16 weeks, maintenance treatment with administration of cyclosporine on weekends proved to safely and effectively prolong maintenance of the therapeutic response.
TREATMENT WITH IMMUNOBIOLOGICS
With the aim of establishing the recommendations on the treatment of psoriasis with immunobiologics, questions regarding indication, efficacy and safety of these medications were structured.
A search was carried out in Medline-PubMed database and the best scientific evidences were selected to answer the clinical questions.
This search encompassed all immunobiologics approved in Brazil for the treatment of plaque psoriasis: adalimumab, etanercept, infliximab, ustekinumab, secukinumab, ixekizumab and guselkumab.
In which conditions is the treatment with immunobiologics indicated?
The indications for the use of immunobiologics in patients older than 18 years of age, with moderate to severe plaque psoriasis, with PASI score above 10 to 12 or involvement of more than 10% of body surface area are:
• Patients that did not respond to the treatment or have contraindications or intolerance to the adequate dose and course of at least one of the systemic drugs or phototherapy (A). 6, 12, 136, 137, • Less than 50% improvement in the baseline PASI or less than 75% improvement in the baseline PASI associated to a significant impact of the disease on the quality of life as measured by the DLQI (Dermatology Life Quality Index) >=10 is considered therapeutic failure.
Some groups of patients with moderate to severe plaque psoriasis were not studied for the treatment with immunobiologics (A). 
Recommendations:
The indications for the use of immunobiologic drugs in patients older than 18 years of age, with moderate to severe plaque psoriasis, with PASI score above 10 or body surface area involvement higher than 10% are: the lack of response to systemic treatment or phototherapy, contraindications or intolerance to the adequate dose and course of at least one of the systemic treatments.
What is the efficacy and risk of etanercept for the treatment of psoriasis?
The treatment with etanercept for moderate to severe plaque psoriasis, for the period of 12 weeks, was effective and safe with the evaluation of the PASI 75 response ( 
Recommendations:
The induction treatment with infliximab in moderate to severe plaque psoriasis for the period of 10 weeks, was effective with the evaluation of the PASI 75 response (65.8-79.6%) and improvement in quality of life with the DLQI score (8.9 to 9.9%), besides being safe, com few mild to moderate side effects reported, mainly infusion reactions, with the doses of 3mg/kg, 5mg/kg or 10mg/kg, on weeks 0, 2 and 6 (Table 3) . 35.5% of those using methotrexate and 18.9% of those using placebo (A). 137 In a study comparing infliximab (n=653) with methotrexate (n=215), here was a significantly better improvement in patients treated with infliximab (78% vs. 42%, p<0.001, NNT=3) and the proportion of patients achieving PASI 90 was significantly higher (p<0.001) in patients in the infliximab group (A).
186
Sixty patients were included in a study, and of these 30 were using etanercept 50mg twice weekly and the other 30 patients were using acitretin 0.4mg/kg/day; 56.7% of the patients in the etanercept group and 26.7% of the patients in the acitretin group showed PASI 75 response (p<0.005, NNT=4) (A).
187
Regarding safety, the study comparing adalimumab with methotrexate showed similar rates of adverse events among patients using methotrexate and adalimumab. Regarding the study that compared etanercept with acitretin, safety data between both groups were also very similar.
In the study that evaluated the efficacy and safety of infliximab and methotrexate for the treatment of psoriasis, severe adverse events were reported more frequently in the group using infliximab, encompassing severe infections (tuberculosis, opportunistic infections such as P. carinii pneumonia, listeriosis, atypical mycobacte- 
Recommendations:
Immunobiologics are more effective in the treatment of moderate to severe plaque psoriasis when compared to the classic treatment. Except for infliximab, immunobiologics are safer and better tolerated when compared to the classic drugs. Studies with infliximab showed higher risk of severe infections and infusion reactions.
Is there a difference in the efficacy of the treatment with immunobiologics in patients with psoriasis that already used one or more immunobiologics in comparison to those patients who never used an immunobiologic?
In a publication presenting integrated data of efficacy results of 12 weeks of two phase 3 studies, where patients were treated with ixekizumab 80mg every two weeks (n=736), ixekizumab Sixty-nine treated with adalimumab were evaluated, which have already had previous treatment with other immunobiologics and/or TNF-alpha blockers (etanercept, efalizumab, alefacept, infliximab or ustekinumab). The comparison was with 16 patients using adalimumab as the first immunobiologic treatment. In relation to the original baseline (beginning of the study), the difference to PASI 75 in the evaluation at 12 weeks was of 27% favoring the group that used immunobiologics for the first time (NNT=4, p=0.004). There was no significant difference between the comparison groups for PASI 75 response rate in the evaluation at 24 and 48 weeks. Of all patients in the study, 19% presented adverse events, and only 29% of these were possibly or probably related to the drug being investigated (B). 190 The evaluation of 282 patients using adalimumab which had not used TNF-alpha blocker previously, was compared to 448 patients on adalimumab, with previous use of TNF-alpha blockers.
In the evaluation at 16 weeks, there was a 22.7% difference for PASI 75 favoring patients who had not been previously treated with TN-F-alpha blockers, compared to the group of patients that had been previously treated with two or more TNF-alpha blockers (NNT=5, p=0.016). the adverse events were similar in both groups, with the presence of infections being the most common (A). 
Recommendations:
In the efficacy evaluations at treatment weeks 12 and 16, adalimumab showed better response rates for the patients who were not previously treated with other immunobiologic drugs or tumor necrosis factor blockers; however, in the evaluations at 24 and 48 weeks this benefit was not observed.
In the efficacy evaluations at treatment weeks 12 and 24, etanercept 50mg demonstrated better response rates in patients that did not receive previous treatment with immunobiologics.
Regarding ixekizumab, there was no difference between those previously treated with other immunobiologics and those not.
-COMBINED TREATMENT
With the aim of establishing the recommendations on the combined treatment of plaque psoriasis with different drugs (immunobiologics, phototherapy and drugs from the classic regimen -Acitretin, Methotrexate and Cyclosporine), a search was carried out using Medline-PubMed database and 24 studies were selected to answer the clinical questions. the first group and all patients from the second group had adverse events, being the main ones increase in creatinine levels, hypertension, hypertriglyceridemia, depression and raised transaminases.
The most common adverse event was increased levels of creatinine (higher than 30%), observed in eight patients (57%) (B).
203
Twenty patients received combined treatment with intramuscular methotrexate 10 mg per week associated to cyclosporine 3.5 mg/kg/day, divided into two doses. The mean combined treatment was 9.5 weeks and median PASI reduction was of 77.4%
(ranging from 51.2 to 90.2) (p<0.001). Fourteen patients had some kind of adverse event, being gastrointestinal and renal and hepatic abnormalities the most common (B).
195
Recommendations:
Although the treatment combination (methotrexate + cyclosporine and methotrexate + acitretin) show superior efficacy data when compared to efficacy data as monotherapy, the lack of studies proving the safety of these associations limit the recommendations for their use in the management of patients with moderate to severe plaque psoriasis. 
The combination of phototherapy (UVB and PUVA) with classic systemic treatments showed higher efficacy than the respective treatments separately, according to evaluation of both PGA 0 or 1 response and PASI 75 response. 
In the comparison of etanercept as monotherapy or associated to NB-UVB phototherapy, there was no difference for PASI 75 or PASI 90 in the evaluation at 24 weeks. However, in the evaluation at 12 and 16 weeks after starting the treatment, there are controversies regarding the benefit of the combined treatment for PASI 90.
With ustekinumab, the association with UVB phototherapy speed up the process of improvement of the lesions on week 6, with a difference of PASI 75 in 67% for the half of the body receiving the combined therapy (NNT=2), in relation to the half of the body that was treated with the immunobiologic alone. 
187
In a study, 478 patients with moderate to severe plaque psoriasis with normal liver and hematologic functions were included. All patients were treated with etanercept 50mg, subcutaneously, twice weekly for 12 weeks, followed by 50mg per week. In the intervention group (n=239), weekly oral methotrexate, in doses of 7.5 mg to 15 mg was added from week 12 to 24. In the comparison group, all patients received etanercept associated to placebo only after the 12 th week (n=211). On week 24, there was a 17% difference in PASI 75 response, favoring patients treated with the combined therapy (NNT=6, p<0.0001); for PASI 50, the difference was of 7% (NNT=15, p=0.01) favoring the group of combined therapy, and for PASI 90, the difference was of 19.6% (NNT=6, p=0.01), also favoring the group receiving the combined therapy. of the patients, 74.9% of the combined therapy group and 59.8% of the monotherapy group had adverse events. The most common events were nasopharyngitis, headache, upper respiratory tract infection and nausea (A).
199
In a double-blind, randomized study, 60 patients with moderate to severe plaque psoriasis allocated into three groups were evaluated: group 1 with 22 patients receiving etanercept 25mg, twice weekly, subcutaneously; group 2 with 20 patients using acitretin 0.4mg/kg/day, orally; group 3 with 18 patients using etanercept 25mg per week, associated to acitretin 0.4mg/kg/day. On week 24, 45%of the patients in group 1, 30% of patients in group 2 and 44% of patients in group 3 achieved PASI 75 (p=0.001 for both groups receiving etanercept in comparison to the patients who were treated with acitretina only). There was no significant difference regarding the variation of the mean values of ALT, AST, cholesterol and triglycerides between the three groups (A).
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In another study, with 24 weeks duration, patients with partial response to methotrexate (at least three months of treatment)
were included and allocated into two groups: the first group (n=28) received etanercept for 24 weeks associated to a short course of oral methotrexate (four weeks); and the second group (n=31) received subcutaneous etanercept and continuous oral methotrexate for 24
weeks. Etanercept was administered subcutaneously, in the dose of 50mg twice weekly every week for 12 weeks, followed by 25 mg twice weekly for another 12 weeks. PGA 0 or 1 response was superior in the group using methotrexate continuously (66.7 vs 37.0%, respectively) (NNT=4, p=0.025). Both comparison groups showed PASI improvement compared to baseline. However, the difference was significant for PASI 75 on week 24 (p=0.013) in the group receiving etanercept associated to continuous methotrexate and there was no significant reduction for PASI 90 (p=0.077). regarding adverse events, there was no difference between the comparison groups, with the most common events being infections, pustular psoriasis on the hands, pneumonia, heart failure/atrial fibrillation (A).
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Recommendations:
In the evaluation of the use of etanercept as monotherapy compared to the immunobiologic associated to methotrexate or acitretin, there was improvement to PASI 75 on week 24 in patients treated with the association. Adverse events were reported in 74.9% of the patients receiving combined therapy and in 59.8% of the patients receiving monotherapy with immunobiologic or the classic treatment.
TREATMENT OF PREGNANT AND BREASTFEEDING WOMEN
Psoriasis is a chronic inflammatory condition that is more frequent in adults and the need for therapeutic intervention in women of child-bearing age is common. With the aim of establishing the recommendations for the treatment of plaque psoriasis in pregnant or breastfeeding women, a search was carried out using Medline-PubMed database, retrieving 324 studies, out of which 43 were selected to answer the clinical questions. 
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It was also observed in one study that the use of low and medium potency did not show significant increase of the risk of fetal growth restriction, on the other hand, those of high and very high potency showed increase of the risk (RR 2.08; 95% CI 1.40-3.10;
p<0.001, NNH=168). There was no association between maternal exposure to topical corticosteroids of all potencies and increased risk of fetal death, premature labor or fetal malformations (B). 
Calcineurin inhibitors (Tacrolimus)
Authors found an association with prematurity and low birth weight. When used topically, calcineurin inhibitors are weakly absorbed systemically (242) (D). Their use is allowed in small areas when there is no other alternative, due to the lack of studies on safety during pregnancy (B). 241 
Vitamin D analogues (Calcipotriol)
Calcipotriol or calcipotriene, vitamin D analogue, when applied in small areas and doses < 10,000 IU/day has a small risk of systemic absorption (D). 210 There are no studies conducted on pregnant women (B). 223 In animal studies, calcipotriol resulted in a higher incidence of skeletal abnormalities, including incomplete ossification of the pubic bones and anterior phalanges (D). 211, 234 When there are no alternatives, the topical use of calcipotriol on small surfaces is allowed, but it should be avoided under occlusive dressings, avoiding systemic absorption and reducing the risk of toxicity (D). The use of dithranol and coal tar is not recommended during pregnancy (D). 
Methotrexate
Methotrexate was shown to be teratogenic and abortive during pregnancy. There are evidences that methotrexate is found on the liver for up to four months after exposure and a prospective review of nine cases of methotrexate exposure prior to pregnancy showed that in four cases, where the exposure took place within six months of the pregnancy, spontaneous abortions occurred (D). 211, 234, 251 There are reports of spontaneous abortions after its use on the first trimester of pregnancy (B). 231 Multiple malformations (craniofacial, skeletal, cardiopulmonary and gastrointestinal) were detected on the 18 th week of gestation in a patient who received the drug on the first week of gestation (C).
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Acitretin
Acitretin, a synthetic derivative of vitamin A, was shown to be teratogenic in animal studies, supporting it being absolutely contraindicated in pregnant women (D). 224 The teratogenic effects associated to retinoids and hypervi- it is paramount that its serum levels be monitored more frequently and, when necessary, dose adjustments be made (B). 238 High levels of cyclosporine in the placenta and/or umbilical cord blood were found in many studies, with 6% of the maternal concentration of cyclosporine reaching the fetus albeit no detection of the drug in the maternal or fetal brain (B).
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A meta-analysis with 15 studies including 410 pregnant women who underwent a transplant and were exposed to cyclos- 
The use of narrowband UVB seems to reduce the serum levels of folate, and can increase the risks of neural tube defects in the fetus/ therefore, the concurrent use of folic acid 5 mg/day is recommended (B). 218 In a prospective study that followed 159 pregnant women, psoralen + UVA (PUVA) did not show an increase in the incidence of fetal malformations or fetal deaths (B). 225, 246 Since psoralen is a known mutagen and teratogen, avoidance of treatment with PUVA during pregnancy is recommended (D). 234 
Immunobiologics
There are reports that the use of infliximab during pregnancy did not cause abnormalities in fetal development (C). 
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Recommendations:
There are evidences that the use of low and medium potency topical corticosteroids are safe for the treatment of the pregnant woman with psoriasis. There seems to be an association of very high potency topical corticosteroids with low birth weight, and it should be avoided.
Since tazarotene has teratogenic potential, it is contraindicated during pregnancy.
Tacrolimus used topically is very little absorbed, however, due to the lack of safety studies in pregnant women, it is indicated to be used on small areas when there is no other therapeutic alternative.
There are no studies with calcipotriol conducted in pregnant women, and it should be avoided in this population.
The use of topical salicylates should be avoided in pregnant women due to the risk of systemic absorption of the salicylate and subsequent fetal risk.
Ultraviolet B phototherapy is the systemic therapy with best evidence of safety during pregnancy. PUVA phototherapy should be avoided during pregnancy due to the teratogenic potential of psoralen.
Despite being classified as category C by the FDA (USFood and Drug Administration Agency), cyclosporine has good evidences of safety for use during pregnancy.
Acitretin is absolutely contraindicated in pregnant women because of its teratogenic potential, and effective contraception must be ensured during its use and for at least two years after ceasing the drug.
Methotrexate is contraindicated during pregnancy because it is teratogenic and abortive.
There are reports that the use of infliximab, etanercept and adalimumab do not alter fetal development, being safe to the fetus when used during pregnancy. Nonetheless, there are no sufficient data for recommending these medications for the treatment of psoriasis in the pregnant woman, and effective contraception is recommended during their use in women of childbearing age.
There are very limited data on the safety of the treatment with ustekinumab, secukinumab, ixekizumab and guselkumab during pregnancy, with not enough data yet to recommend their use in pregnant women; effective contraception is recommended during their use in women of childbearing age.
Treatment of plaque psoriasis in breastfeeding women
Topical Corticosteroids
The first line of treatment for breastfeeding mothers is limited to emollients and low to medium potency topical corticosteroids (D). 232 Topical corticosteroids have been proven safe during breastfeeding (C). 250 There is one report of hypertensive crisis in an infant after maternal use of high potency topical corticosteroid (C). 244 
Calcipotriol
Regarding calcipotriol, a vitamin D analogue, it presents a low risk of systemic absorption when used in small doses < 10,000 IU/day, however, there are no reports of its use during breastfeeding (D). 223 
Tar Derivatives
Coal tar can be transferred to the infant during breastfeeding through skin-to-skin or skin-to-mouth contact (C). 243 Cases of detection of tar derivatives in breast milk have been reported (D). 232 
Phototherapy
Ultraviolet B (UVB) phototherapy is compatible with breastfeeding. Regarding PUVA, topical psoralen has little systemic absorption, however, it is unknown if it is absorbed into breast milk.
PUVA phototherapy is contraindicated during breastfeeding (B). 
Acitretin
Acitretin should be avoided during breastfeeding due to its cumulative toxic effect. Breastfeeding infants are not capable of excreting the drug through the kidneys or liver due to the immaturity of these organs; this would increase the serum levels of the drug and it could reach toxic levels.
It was recently described that there are traces of acitretin 
Methotrexate
Methotrexate has reports of transference into breast milk in small concentrations, and can be deposited in the child's tissues for many months. Due to the limited number of studies in breastfeeding women and analysis of its long term effects in infants, its use is not recommended (C). 229 Two-hourly samples of breast milk from a patient treated with a first dose of 22.5mg of methotrexate for postpartum choriocarcinoma showed it was excreted in small concentrations in the breast milk. The maximum level of methotrexate measured in the breast milk was around 3% of the maximum maternal serum level, with the higher ratio milk-serum of 0.08 at 10 hours (D). 251 The meaning of these measures is uncertain due to limited reports, and its use is contraindicated during breastfeeding (B), 210 (D). 
Cyclosporine
There are reports of infants, born from renal transplant recipients using cyclosporine during breastfeeding, who did not develop renal toxicity or other side effects, with undetectable levels of cyclosporine (B), 237 even though other reports show cytotoxicity and suggest avoiding the drug during breastfeeding (C). 
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Etanercept is only found in small concentrations in breast milk and is undetectable in the blood of breastfeeding infants (C). 213, 235 In all case reports of mothers using etanercept, the breastfeeding infants achieved all development milestones. The authors described the concentration in breast milk of 5 ng/ml and etanercept was not detected in the infants' blood. Because it is a large protein, oral absorption of etanercept is believed to be minimal or absent (D). 232 Adalimumab and infliximab had similar results to etanercept and seem to be safe for use during breastfeeding according to some reports (C). 213, 221, 230, 245 Ixekizumab is excreted in low levels in breast milk from cynomolgus monkeys, but it is unknown if it is excreted in human breast milk or if it is systemically absorbed after ingestion. It is a large protein molecule (molecular weight of 146,000 kDa), therefore, absorption is unlikely after the first weeks after delivery. The same is described for secukinumab (molecular weight 151,000 kDa) (D). 239 Data on monoclonal antibodies anti-IL-12/23 are very immature to make any recommendations. Since ustekinumab has a molecular weight of 149,000 kDa, the amount in breast milk is likely to be very low and the absorption is unlikely due to its destruction in the infant's gastrointestinal tract (D). 239 The effects of the use of ustekinumab during breastfeeding were studied in cynomolgus monkeys, in which low levels of ustekinumab (1/1000 of the level found in maternal serum) were found in breast milk. There are no reports of breastfeeding in humans; however, due to the fact that other immunoglobulins and proteins are present in colostrum, it is suggested that ustekinumab is excreted in breast milk (B).
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Recommendations:
Topical corticosteroids have been proven safe during breastfeeding.
There are no reports on the use of calcipotriol during breastfeeding.
Ultraviolet B phototherapy is the safest modality of systemic treatment to be indicated during breastfeeding. PUVA phototherapy should be avoided.
Methotrexate, acitretin, cyclosporine and psoralen (PUVA) are contraindicated during breastfeeding.
Adalimumab, infliximab and etanercept are safe for use during breastfeeding.
The lack of data on ustekinumab, ixekizumab, secukinumab and guselkumab does not allow to recommend their use during breastfeeding.
MEDICATIONS ASSOCIATED TO THE DEVELOPMENT OR AGGRAVA-
TION OF PSORIASIS
With the aim of establishing the recommendations on systemic medications associated to the development or aggravation of psoriasis, a search was carried out using Medline-PubMed database, and the best scientific evidences were selected to answer the clinical questions. This search encompassed drugs that have been historically associated to the development and/or aggravation of psoriasis: angiotensin converting enzyme I inhibitors, angiotensin II receptor antagonists, lithium, beta-blockers, anti-inflammatories, antimalarials and interferon.
9. Which systemic medications are associated to the development or aggravation of psoriasis?
TNF-alpha blockers
Patients with chronic inflammatory conditions being treated with TNF-alpha blockers can progress with psoriasis as a paradoxical effect, also known as reactive psoriasis, most frequently reported in patients with inflammatory bowel disease (C). [252] [253] [254] [255] [256] Many studies evidenced this relationship, with incidence ranging from 1.6% to 2.5% (253-256) (C). Smoking (C) 252, 256 and female gender (C) 254, 256 were considered significant among the factors possibly related with the development of psoriasis as a paradoxical effect.
Interferon Alpha
During treatment with interferon alpha for the Hepatitis C, 36
cases of patients who developed psoriasis lesions (aggravation in 22 cases and triggering in 14 cases) were reported in 32 publications (C). Twenty-three psoriasis patients using betablockers first developed psoriasis after commencing the drug in seven cases, and this number was statistically significant when compared to the control group (psoriasis patients with no previous use of betablocker) -p<0.001. four of these patients had a generalized presentation (severe) of psoriasis and in three the symptoms remitted after discontinuation (B). .01), demonstrating that the use of lithium was associated to a small risk of an increased incidence of psoriasis (B). 264 Patients with psychiatric disorders that received lithium for the first time developed psoriasis in 6% of cases (of the 51 patients receiving lithium, three developed lesions); compared to the control group, p value was not significant (B). 
Recommendations:
TNF alpha blockers can paradoxically cause psoriasiform lesions in patients with chronic inflammatory conditions, being more frequent in inflammatory bowel disease, occurring in 1.6-2.5%
of patients.
Results of the largest studies regarding betablockers and lithium are still controversial because they are drugs with considerable evidences, however insufficient, to cause or aggravate psoriasis.
Therapy with interferon alpha, nonsteroidal anti-inflammatories, angiotensin receptor antagonists and ACE inhibitors seem to trigger or exacerbate preexisting psoriasiform lesions, although with weak evidences of causal relationship. q
